Immunoglobulin treatment study for antibody deficiency
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study looks at how well immunoglobulin replacement therapy works in people with low antibody levels and how it affects the immune system. It aims to help improve treatment for primary antibody immunodeficiencies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 5 and 50 years old.
- You have a confirmed diagnosis of primary antibody immunodeficiency, which means your body doesn't make enough antibodies to fight infections.
- You have had low levels of antibodies (IgG, IgA, or IgM) in your blood, or you did not respond well to vaccines.
- You are currently receiving or about to start regular immunoglobulin replacement therapy (IVIG or SCIG).
- You do not have other conditions that cause low antibodies (like cancer, kidney disease, or untreated HIV).
- You have not taken immune-suppressing drugs in the last 3 months (except immunoglobulin therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
This study tests whether a new antibody treatment called TAK-664 is safe and works for people with primary immunodeficiency who have never had antibody replacement before. It compares the new treatment to a standard approach, with the goal of helping prevent infections and improve quality of life.
This study tests an intravenous immunoglobulin (IVIG) treatment, which is a way of giving you antibodies to help fight infections. It aims to see if this treatment is safe and effective for people with certain immune deficiencies.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This study collects blood (and sometimes related samples) to learn how genes and the immune system work in people with primary immunodeficiency (PID) or in family members who may not have it. The goal is to improve understanding of rare immune conditions and help guide future care.
This study tests if a moderate exercise program can help people with certain antibody deficiencies. It aims to see if exercise improves immune function in people who are not taking immunoglobulin therapy.
Hear when a new Primary Immunodeficiency Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.